tibolone + estradiol-norethisterone

Phase 3Completed

1 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Sexual Dysfunction

Conditions

Sexual Dysfunction

Trial Timeline

Mar 23, 2004 → Nov 15, 2005

NCT ID

NCT00413764

About tibolone + estradiol-norethisterone

tibolone + estradiol-norethisterone is a phase 3 stage product being developed by Organon for Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00413764. Target conditions include Sexual Dysfunction.

What happened to similar drugs?

3 of 8 similar drugs in Sexual Dysfunction were approved

Approved (3) Terminated (0) Active (5)

🔄DapoxetineJohnson & JohnsonPhase 3

✅sildenafilPfizerApproved

✅AlfuzosinSanofiApproved

🔄AVANAFIL + placeboSanofiPhase 3

✅Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved

🔄Bremelanotide + PlaceboPalatin TechnologiesPhase 3

🔄BremelanotidePalatin TechnologiesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00413764	Phase 3	Completed	Mar 23, 2004	Nov 15, 2005	Sexual Dysfunction

Competing Products

18 competing products in Sexual Dysfunction

See all competitors

Product	Company	Stage	Hype Score
Dapoxetine	Johnson & Johnson	Phase 3	40
Gardasil Vaccine	Merck	Pre-clinical	26
sildenafil	Pfizer	Approved	43
sildenafil	Pfizer	Phase 2	35
CP-866,087 + CP-866,087 + CP-866,087 + Placebo	Pfizer	Phase 2	35
PF-00446687 + Placebo	Pfizer	Phase 2	35
Bremelanotide	Pfizer	Phase 2	35
Sildenafil 100 mg + Placebo	Pfizer	Phase 2	35
Alfuzosin	Sanofi	Approved	43
AVANAFIL + placebo	Sanofi	Phase 3	40
Levitra (Vardenafil, BAY38-9456) + Placebo	Bayer	Approved	40
Placebo + 0.5 mgTestosterone + 10 mg Buspirone	Brain Biotech	Phase 2	25
Placebo + Testosterone + Buspirone hydrochloride	Brain Biotech	Phase 2	25
Placebo + Sildenafil + Testosterone	Brain Biotech	Phase 2	25
Bremelanotide + Placebo	Palatin Technologies	Phase 3	30
bremelanotide	Palatin Technologies	Phase 2	25
Bremelanotide	Palatin Technologies	Phase 3	30
EVO100 + Placebo	Evofem Biosciences	Phase 3	30